semaglutide compound end date Compounded for Weight Loss The Risks of Compounded Semaglutide

Many patients use this as a bridge after discontinuing therapeutic doses, preserving 50-70% of appetite suppression while reducing medication burden and cost

Semaglutide produces greater weight loss as monotherapy (15-17% vs 11.8%), but the two peptides can be combined for additive effects

Nutr Metab (Lond) 17:90

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily used to manage type 2 diabetes and, more recently, obesity

Metformin was the most common oral glucose-lowering therapy used, totalling 43% of all patients who were prescribed adjunctive therapies

See chart below for comparison of GLP-1 agents